UNSPSC 51294507: Ifoxetine

This classification denotes an antidepressant agent with the molecular formula C13H19NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LHH887104B, chemically known as 3-piperidinol, 4-(2,3-dimethylphenoxy)-, cis- but generally known as ifoxetine, which bears US NIH Compound Identifier 71971. European Medicines Agency schedules Ifoxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08126MIG.

UNSPSC 51294507 Ifoxetine is a Commodity code that captures pharmaceutical products procured by state and local health agencies, though recent solicitations under this code show activity centered on naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products rather than ifoxetine specifically. State and local issuing bodies purchasing under this code include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple states and localities. Seminole County, Florida, for instance, recently issued an IFB seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives with quarterly deliveries, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administrated by the Minnesota Department of Administration issued an RFP to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon. Vendors competing for these contracts must meet federal and state compliance requirements including FDA registration, cGMP certification, Drug Supply Chain Security Act adherence, E-Verify employment verification, and specific insurance coverages such as commercial general liability and professional liability.

Recent procurement activity is concentrated in Florida and the Upper Midwest through cooperative vehicles. The Seminole County IFB (S1070000015802, due July 26, 2023) requires vendors to provide unit pricing for naloxone and deactivation systems with quarterly deliveries to a single county health facility and represents direct county procurement for community health support. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, signaling state-level interest in alternative pharmaceutical supply models but stopping short of formal competitive solicitation. The MMCAP RFP (posted January 20, 2026, due March 26, 2026) represents the broadest geographic reach, requiring manufacturers to supply generic pharmaceuticals through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with competitive evaluation weighted 75 percent on price competitiveness and contract effectiveness July 1, 2026. The code shows limited recent activity directly under the ifoxetine taxonomy itself, with actual purchasing concentrated on naloxone and OTC generics across health department and cooperative purchasing channels.